PMID-sentid Pub_year Sent_text comp_official_name comp_offset protein_name organism prot_offset 33844153-11 2021 Indeed, RNA data analyses revealed upregulations of genes involved in ceramide synthesis in brain endothelial cells of EAE mice (LASS6/CERS6, LASS3/CERS3, UGCG, ELOVL6, and ELOVL4). Ceramides 70-78 ceramide synthase 6 Mus musculus 129-134 25173988-5 2014 In macrophages, we demonstrated that interferon gamma (IFN-gamma)-induced CerS6 upregulation was amplified by 17ss-estradiol, an action that was further accompanied by increased upregulation of tumor necrosis factor alpha (TNF-alpha). 17ss-estradiol 110-124 ceramide synthase 6 Mus musculus 74-79 23832510-6 2014 Decreased ceramide levels reflected their reduced de novo synthesis, due to inhibition of the activity of serine-palmitoyl transferase (SPT) and the expression of its SPTLC3 catalytic subunit, as well as reduced ceramide synthase (CerS) activity related to reduced expression of CerS1 and CerS6. Ceramides 10-18 ceramide synthase 6 Mus musculus 289-294 23760501-0 2013 Inactivation of ceramide synthase 6 in mice results in an altered sphingolipid metabolism and behavioral abnormalities. Sphingolipids 66-78 ceramide synthase 6 Mus musculus 16-35 23760501-8 2013 Using newly developed antibodies that specifically recognize the CerS6 protein we show that the endogenous CerS6 protein is N-glycosylated and expressed in several tissues of mice, mainly kidney, small and large intestine, and brain. Nitrogen 124-125 ceramide synthase 6 Mus musculus 65-70 23760501-8 2013 Using newly developed antibodies that specifically recognize the CerS6 protein we show that the endogenous CerS6 protein is N-glycosylated and expressed in several tissues of mice, mainly kidney, small and large intestine, and brain. Nitrogen 124-125 ceramide synthase 6 Mus musculus 107-112 22544924-7 2012 Downregulation of CerS6 by RNA interference or endogenous upregulation of C(16:0)-Cer mediated by palmitic acid in RAW 264.7 macrophages led to a significant reduction or increase in NO/TNF-alpha release, respectively. Palmitic Acid 98-111 ceramide synthase 6 Mus musculus 18-23 34358645-2 2021 We have demonstrated that Ceramide Synthase 6 (CerS6) and C16:0-ceramide mediate response to folate stress in cultured cells. Folic Acid 93-99 ceramide synthase 6 Mus musculus 26-45 34358645-2 2021 We have demonstrated that Ceramide Synthase 6 (CerS6) and C16:0-ceramide mediate response to folate stress in cultured cells. Folic Acid 93-99 ceramide synthase 6 Mus musculus 47-52 34358645-6 2021 RESULTS: Our study shows that alterations in dietary FA elicit multiple sphingolipid responses mediated by CerS6 in mouse livers. Sphingolipids 72-84 ceramide synthase 6 Mus musculus 107-112 34358645-11 2021 Untargeted liver metabolomic analysis concurred with the targeted measurements and showed broad effects of dietary FA and CerS6 status on multiple lipid classes including sex-specific effects on phosphatidylethanolamines and diacylglycerols. Phosphatidylethanolamines 195-220 ceramide synthase 6 Mus musculus 122-127 34358645-11 2021 Untargeted liver metabolomic analysis concurred with the targeted measurements and showed broad effects of dietary FA and CerS6 status on multiple lipid classes including sex-specific effects on phosphatidylethanolamines and diacylglycerols. Diglycerides 225-240 ceramide synthase 6 Mus musculus 122-127 34358645-12 2021 CONCLUSIONS: Our study demonstrates that both dietary FA and CerS6 status exhibit pleiotropic and sex-dependent effects on liver metabolism, including hepatic sphingolipids, diacylglycerols, long chain fatty acids, and phospholipids. Diglycerides 174-189 ceramide synthase 6 Mus musculus 61-66 34358645-12 2021 CONCLUSIONS: Our study demonstrates that both dietary FA and CerS6 status exhibit pleiotropic and sex-dependent effects on liver metabolism, including hepatic sphingolipids, diacylglycerols, long chain fatty acids, and phospholipids. long chain fatty acids 191-213 ceramide synthase 6 Mus musculus 61-66 34358645-12 2021 CONCLUSIONS: Our study demonstrates that both dietary FA and CerS6 status exhibit pleiotropic and sex-dependent effects on liver metabolism, including hepatic sphingolipids, diacylglycerols, long chain fatty acids, and phospholipids. Phospholipids 219-232 ceramide synthase 6 Mus musculus 61-66 33951438-3 2021 Here, we show that activated T cells isolated from aging mice have elevated C14/C16 ceramide accumulation in mitochondria, generated by ceramide synthase 6, leading to mitophagy/mitochondrial dysfunction. Ceramides 84-92 ceramide synthase 6 Mus musculus 136-155 25295788-0 2014 Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Ceramides 38-46 ceramide synthase 6 Mus musculus 16-21 25295788-0 2014 Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Glucose 83-90 ceramide synthase 6 Mus musculus 16-21 25295788-5 2014 Conversely, CerS6-deficient (CerS6(Delta/Delta)) mice exhibit reduced C16:0 ceramides and are protected from high-fat-diet-induced obesity and glucose intolerance. Ceramides 76-85 ceramide synthase 6 Mus musculus 12-17 25295788-5 2014 Conversely, CerS6-deficient (CerS6(Delta/Delta)) mice exhibit reduced C16:0 ceramides and are protected from high-fat-diet-induced obesity and glucose intolerance. Glucose 143-150 ceramide synthase 6 Mus musculus 12-17 25295788-6 2014 CerS6 deletion increases energy expenditure and improves glucose tolerance, not only in CerS6(Delta/Delta) mice, but also in brown adipose tissue- (CerS6(DeltaBAT)) and liver-specific (CerS6(DeltaLIVER)) CerS6 knockout mice. Glucose 57-64 ceramide synthase 6 Mus musculus 0-5 25295788-8 2014 These experiments highlight CerS6 inhibition as a specific approach for the treatment of obesity and type 2 diabetes mellitus, circumventing the side effects of global ceramide synthesis inhibition. Ceramides 168-176 ceramide synthase 6 Mus musculus 28-33 34358645-0 2021 Ceramide Synthase 6 mediates sex-specific metabolic response to dietary folic acid in mice. Folic Acid 72-82 ceramide synthase 6 Mus musculus 0-19 34805245-0 2021 Dietary Folic Acid Alters Metabolism of Multiple Vitamins in a CerS6- and Sex-Dependent Manner. Folic Acid 8-18 ceramide synthase 6 Mus musculus 63-68 30706713-10 2019 The effect of celastrol on lipid metabolism was significantly reduced in Fxr-null mice, resulting in decreased Cers6 and Acer2 mRNAs compared to wild-type mice. celastrol 14-23 ceramide synthase 6 Mus musculus 111-116 31676768-9 2019 Blocking ER stress abrogated the detrimental effects of CerS6 on palmitate-induced SREBP-1 cleavage. Palmitates 65-74 ceramide synthase 6 Mus musculus 56-61 32902157-4 2020 Under a reduced CERS6 expression condition, the ceramide profile became altered, which was determined to be associated with decreased cell migration and invasion activities in vitro. Ceramides 48-56 ceramide synthase 6 Mus musculus 16-21 32902157-6 2020 Based on these findings, we consider that ceramide synthesis by CERS6 has important roles in lung cancer migration and metastasis. Ceramides 42-50 ceramide synthase 6 Mus musculus 64-69 30655217-2 2019 Recent genetic mouse studies suggest that specific sphingolipid C16:0 ceramide produced by ceramide synthase 6 (CerS6) plays an important role in the development of insulin resistance. Sphingolipids 51-63 ceramide synthase 6 Mus musculus 91-110 30655217-2 2019 Recent genetic mouse studies suggest that specific sphingolipid C16:0 ceramide produced by ceramide synthase 6 (CerS6) plays an important role in the development of insulin resistance. Sphingolipids 51-63 ceramide synthase 6 Mus musculus 112-117 30655217-2 2019 Recent genetic mouse studies suggest that specific sphingolipid C16:0 ceramide produced by ceramide synthase 6 (CerS6) plays an important role in the development of insulin resistance. Ceramides 70-78 ceramide synthase 6 Mus musculus 91-110 30655217-2 2019 Recent genetic mouse studies suggest that specific sphingolipid C16:0 ceramide produced by ceramide synthase 6 (CerS6) plays an important role in the development of insulin resistance. Ceramides 70-78 ceramide synthase 6 Mus musculus 112-117 30655217-11 2019 RESULTS: CerS6 expression were significantly elevated in the liver and brown adipose, this was correlated with significantly elevated C16:0 ceramide concentrations in plasma and liver. Ceramides 140-148 ceramide synthase 6 Mus musculus 9-14 30655217-12 2019 Treatment with CerS6 ASO selectively reduced CerS6 expression by ~90% predominantly in the liver and this CerS6 KD resulted in a significant reduction of C16:0 ceramide by about 50% in both liver and plasma. Ceramides 160-168 ceramide synthase 6 Mus musculus 15-20 30655217-13 2019 CerS6 KD resulted in lower body weight gain and accompanied by a significant reduction in whole body fat and fed/fasted blood glucose levels (1% reduction in HbA1c). Glucose 126-133 ceramide synthase 6 Mus musculus 0-5 30655217-14 2019 Moreover, ASO-mediated CerS6 KD significantly improved oral glucose tolerance (during oGTT) and mice displayed improved insulin sensitivity. Glucose 60-67 ceramide synthase 6 Mus musculus 23-28 30655217-17 2019 CerS6 should specifically be targeted for the reduction of C16:0 ceramides, that results in amelioration of insulin resistance, hyperglycemia and obesity. Ceramides 65-74 ceramide synthase 6 Mus musculus 0-5 30655217-18 2019 CerS6 mediated C16:0 ceramide reduction could be a potentially attractive target for the treatment of insulin resistance, obesity and type 2 diabetes. Ceramides 21-29 ceramide synthase 6 Mus musculus 0-5 30054909-0 2018 CerS6 regulates cisplatin resistance in oral squamous cell carcinoma by altering mitochondrial fission and autophagy. Cisplatin 16-25 ceramide synthase 6 Mus musculus 0-5 30054909-5 2018 Therefore, we investigated the role of CerS6 in the susceptibility of OSCC cells to cisplatin. Cisplatin 84-93 ceramide synthase 6 Mus musculus 39-44 30054909-7 2018 We found lower CerS6 expression in cisplatin-resistant OSCC cells. Cisplatin 35-44 ceramide synthase 6 Mus musculus 15-20 30054909-8 2018 Overexpression of CerS6 with lentivirus-encoded CerS6 complementary DNA in cisplatin-resistant OSCC cells increased cisplatin sensitivity. Cisplatin 75-84 ceramide synthase 6 Mus musculus 18-23 30054909-8 2018 Overexpression of CerS6 with lentivirus-encoded CerS6 complementary DNA in cisplatin-resistant OSCC cells increased cisplatin sensitivity. Cisplatin 75-84 ceramide synthase 6 Mus musculus 48-53 30054909-8 2018 Overexpression of CerS6 with lentivirus-encoded CerS6 complementary DNA in cisplatin-resistant OSCC cells increased cisplatin sensitivity. Cisplatin 116-125 ceramide synthase 6 Mus musculus 18-23 30054909-8 2018 Overexpression of CerS6 with lentivirus-encoded CerS6 complementary DNA in cisplatin-resistant OSCC cells increased cisplatin sensitivity. Cisplatin 116-125 ceramide synthase 6 Mus musculus 48-53 30054909-9 2018 Overexpression of CerS6 enhanced mitochondrial fission and apoptosis and attenuated cisplatin-induced autophagy in cisplatin-resistant OSCC cells. Cisplatin 84-93 ceramide synthase 6 Mus musculus 18-23 30054909-9 2018 Overexpression of CerS6 enhanced mitochondrial fission and apoptosis and attenuated cisplatin-induced autophagy in cisplatin-resistant OSCC cells. Cisplatin 115-124 ceramide synthase 6 Mus musculus 18-23 30054909-10 2018 Further investigation indicated that CerS6 might function through altering calpain expression to enhance cisplatin sensitivity. Cisplatin 105-114 ceramide synthase 6 Mus musculus 37-42 30054909-11 2018 Cisplatin-resistant OSCC cells xenografted onto a nude mouse model confirmed that CerS6 enhanced cisplatin chemotherapy sensitivity to reduce tumor volume. Cisplatin 0-9 ceramide synthase 6 Mus musculus 82-87 30054909-11 2018 Cisplatin-resistant OSCC cells xenografted onto a nude mouse model confirmed that CerS6 enhanced cisplatin chemotherapy sensitivity to reduce tumor volume. Cisplatin 97-106 ceramide synthase 6 Mus musculus 82-87 30054909-12 2018 These data indicate that CerS6 could mediate an effective response to cisplatin in chemoresistant OSCC. Cisplatin 70-79 ceramide synthase 6 Mus musculus 25-30 29739864-4 2018 The sex difference was due in part to testosterone-mediated repression of ceramide synthase 6. Testosterone 38-50 ceramide synthase 6 Mus musculus 74-93 29374263-4 2018 While CerS6-deficient mice are protected from T cell mediated colitis, in the T cell independent DSS model lack of CerS6 resulted in a more rapid onset of disease symptoms. dss 97-100 ceramide synthase 6 Mus musculus 115-120 29472233-7 2018 Mechanistically, IL-1beta treatment of isolated neutrophils induced nuclear localization of ceramide synthase 6 and synthesis of C16-ceramide, which was inhibited by IL-1RA or fumonisin B1, an inhibitor of ceramide synthesis. fumonisin B1 176-188 ceramide synthase 6 Mus musculus 92-111 29127192-2 2018 One class of these, the ceramides, constitutes a family of molecules that differ in structure and are synthesized by distinct enzymes, ceramide synthase (CerS)1-CerS6. Ceramides 24-33 ceramide synthase 6 Mus musculus 161-166 29374263-0 2018 Ceramide Synthase 6 Deficiency Enhances Inflammation in the DSS model of Colitis. dss 60-63 ceramide synthase 6 Mus musculus 0-19 29374263-5 2018 CerS6-deficient mice maintained low levels of C16-ceramide after DSS treatment, but the inflammatory lipid sphingosine-1-phosphate was significantly increased in colon tissue. N-palmitoylsphingosine 46-58 ceramide synthase 6 Mus musculus 0-5 29374263-5 2018 CerS6-deficient mice maintained low levels of C16-ceramide after DSS treatment, but the inflammatory lipid sphingosine-1-phosphate was significantly increased in colon tissue. dss 65-68 ceramide synthase 6 Mus musculus 0-5 28812434-6 2017 [Pemetrexed + sildenafil] lethality was enhanced by the histone deacetylase inhibitors AR42 and sodium valproate; AR42 and valproate as single agents also rapidly reduced the expression of PD-L1, PD-L2 and ODC, and increased expression of MHCA and CerS6. Pemetrexed 1-11 ceramide synthase 6 Mus musculus 248-253 29416631-8 2018 Cladoloside C2 exerted antitumor activity through the activation of Fas/CerS6/p38 kinase/JNK/caspase-8 without showing any toxicity in xenograft mouse models. cladoloside 0-11 ceramide synthase 6 Mus musculus 72-77 28812434-6 2017 [Pemetrexed + sildenafil] lethality was enhanced by the histone deacetylase inhibitors AR42 and sodium valproate; AR42 and valproate as single agents also rapidly reduced the expression of PD-L1, PD-L2 and ODC, and increased expression of MHCA and CerS6. Sildenafil Citrate 14-24 ceramide synthase 6 Mus musculus 248-253 28812434-6 2017 [Pemetrexed + sildenafil] lethality was enhanced by the histone deacetylase inhibitors AR42 and sodium valproate; AR42 and valproate as single agents also rapidly reduced the expression of PD-L1, PD-L2 and ODC, and increased expression of MHCA and CerS6. Valproic Acid 96-112 ceramide synthase 6 Mus musculus 248-253 26650179-5 2016 CERS6 knockdown in NSCLC cells altered the ceramide profile, resulting in decreased cell migration and invasion in vitro, and decreased the frequency of RAC1-positive lamellipodia formation while CERS6 overexpression promoted it. Ceramides 43-51 ceramide synthase 6 Mus musculus 0-5 26650179-8 2016 Together, these results indicate that CERS6-dependent ceramide synthesis and maintenance of ceramide in the cellular membrane are essential for lamellipodia formation and metastasis. Ceramides 54-62 ceramide synthase 6 Mus musculus 38-43 26650179-8 2016 Together, these results indicate that CERS6-dependent ceramide synthesis and maintenance of ceramide in the cellular membrane are essential for lamellipodia formation and metastasis. Ceramides 92-100 ceramide synthase 6 Mus musculus 38-43 25833068-8 2015 In vitro, the genetic deletion of CerS6 enhanced the activation status of IFN-gamma/TNF-alpha-stimulated neutrophils, as shown by increased expression of nitric oxide and CD11b and an increased adhesion capacity. Nitric Oxide 154-166 ceramide synthase 6 Mus musculus 34-39